Training Young Doctors, Pharmacists and Engineers in Oncology Research
The cancer genome, targeted therapy, immunotherapy… A real revolution is under way in Oncology. ” Be a part of the next change in oncology ” is the title of the new international drive launched by Gustave Roussy (France) to recruit young doctors, pharmacists and engineers in France, Europe and the rest of the world. This campaign is aiming to attract the most talented individuals who have followed a dual course in Biology, so that Gustave Roussy can train them to take on the great challenges posed by the Oncology of the future.
Supervised by Gustave Roussy’s specialised researchers, they will work on key topics in laboratories provided with the most advanced equipment. They will benefit from personalised support in relation to their career plans. Three-year research contracts to work with the Institute’s expert researchers lead to presentation of a doctoral thesis in Sciences.
Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for a supplemental New Drug Application (sNDA) for Pfizer’s breast cancer medication, IBRANCE® (palbociclib). If approved, the sNDA would expand the approved use of IBRANCE to reflect findings from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant versus fulvestrant plus placebo in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) metastatic breast cancer, regardless of menopausal status, whose disease progressed after endocrine therapy, including those with and without prior treatment for their metastatic disease. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is April 2016. read more
Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). ISIS-SOD1Rx is part of Isis’ strategic collaboration with Biogen to discover and develop antisense drugs to treat neurological diseases. ISIS-SOD1Rx, previously referred to as ISIS-BIIB3Rx, is a Gen. 2.0+ antisense drug designed to reduce the production of superoxide dismutase 1 (SOD1). A mutation in the SOD-1 gene results in an inherited form of ALS, referred to as SOD1-ALS. SOD1-ALS is the second most common familial form of ALS, accounting for up to 20 percent of familial ALS. Familial ALS represents approximately 10 percent of all cases of ALS. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression. read more
Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
HOUSTON & TOKYO–(BUSINESS WIRE)–Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM, “Bellicum”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that Agensys, Inc. (“Agensys”), an affiliate of Astellas, and Bellicum have entered into a global license agreement, granting Bellicum rights to develop and commercialize adoptive cell therapies, including CAR-T cells, for tumors expressing Prostate Stem Cell Antigen (PSCA) using PSCA technology, both in-licensed and developed at Agensys. read more
International Conference on Dengue Prevention and Control Kicks off at NCKU
TAINAN, Taiwan–(BUSINESS WIRE)–The International Conference on Dengue Prevention and Control kicked off at National Cheng Kung University (NCKU), Tainan, Taiwan, on December 7, with dengue experts from 12 countries to strengthen regional capacity to respond to dengue threats and ensure global health security. Minister Been-Huang Chiang of Health and Welfare said at the opening ceremony that the dengue fever outbreak is severe this year in the southern part of Taiwan, especially in Tainan and gladly the outbreak has stopped under the lead of Mayor Ching-Te Lai.
The international cooperation and assistance is very important to fight against epidemic disease, according to Minister Chiang.
Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting
CHESHIRE, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Company highlighted significant progress in its early- and late-stage rare disease portfolio and provided updates on key aspects of its long-term growth strategy at an Investor Day meeting held in New York. read more
Lymphoseek® Technically Successful in Evaluation of Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy
DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that results from an investigator-initiated retrospective analysis demonstrated Lymphoseek® (technetium Tc 99m tilmanocept) injection was successful in lymph node identification rate, node-positivity rate, and number of total nodes evaluated in sentinel lymph node biopsy (SLNB) procedures in clinically node-negative breast cancer patients undergoing neoadjuvant chemotherapy (NAT) compared to patients undergoing initial surgical treatment. These findings suggest that Lymphoseek offers breast surgeons the confidence to specifically identify and remove sentinel lymph nodes in this patient population. Results of the study conducted at the University of California, San Diego, School of Medicine, led by Anne Wallace M.D., professor of surgery, and Jonathan Unkart, M.D., Department of Surgery, UC San Diego Health, were presented today at the San Antonio Breast Cancer Conference in San Antonio, Texas. read more
AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy
PRINCETON, N.J., & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results from a post-hoc early time course subanalysis of the Phase 3 AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy) trial. The subanalysis demonstrated Eliquis (apixaban) was comparable to conventional therapy (subcutaneous enoxaparin overlapped and followed by oral warfarin dose-adjusted to an international normalized ratio of 2.0 to 3.0) in recurrent VTE and VTE-related death with significantly less major bleeding during the first 7, 21 and 90 days after starting treatment. These data were published in Thrombosis and Haemostasis. read more
/PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company’s ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS. The preliminary comparative data suggest that adenoviral delivery of zinc finger nucleases (ZFNs) to T-cells may be uniquely immune-stimulatory for both acute control of infection, and importantly, HIV reservoir reduction. read more
BONESUPPORT™ Announces Results Of CERAMENT™|BONE VOID FILLER Prospective Pilot Study Demonstrating Complete Bone Remodeling In Benign Bone Tumors
– 93% of patients had full or partial cyst resolution at 12 months
– No post-operative infections reported during follow-up period
– No fractures reported during the follow-up period
LUND, Sweden, Dec. 10, 2015 /PRNewswire/ — BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that the Company’s platform technology, CERAMENT™ has proven effective in the management of benign bone tumors in a prospective pilot study. The results were published in the December issue of Biomed Central Musculoskeletal Disorders. read more
Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud
Novo Nordisk and IBM Watson Health today announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The agreement combines Novo Nordisk’s deep understanding of diabetes with IBM’s leadership in cognitive computing.
The companies will explore possibilities for improved diabetes care via insights from real-time, real–world evidence of Novo Nordisk diabetes treatments and devices. By harnessing the potential of the Watson Health Cloud, Novo Nordisk aims to further advance its offerings to people living with diabetes and their healthcare professionals.
Commenting on the agreement, Jakob Riis, executive vice president, Novo Nordisk said: “Working with ambitious partners like IBM Watson Health helps us explore the opportunities presented by an increasingly digitalised healthcare system. We aim to leverage our combined capabilities to improve the lives of people with diabetes by making the management of the condition more simple, effective and measurable.
IBM Watson is the first commercially available cognitive computing platform and represents a new era of computing. The platform, delivered through the cloud, processes vast amounts of big data to uncover patterns and insights, understands complex questions posed in natural language, proposes evidence-based answers, and learns from each interaction. The Watson Health Cloud is a development platform for health and wellness solutions.